Jounce Therapeutics, Inc. (JNCE): Price and Financial Metrics

Jounce Therapeutics, Inc. (JNCE): $1.88

0.05 (-2.59%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

A

Add JNCE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#35 of 388

in industry

JNCE Price/Volume Stats

Current price $1.88 52-week high $5.87
Prev. close $1.93 52-week low $0.58
Day low $1.88 Volume 11,600,600
Day high $1.93 Avg. volume 2,457,142
50-day MA $1.59 Dividend yield N/A
200-day MA $1.99 Market Cap 98.95M

JNCE Stock Price Chart Interactive Chart >


Jounce Therapeutics, Inc. (JNCE) Company Bio


Jounce Therapeutics, Inc. focuses on developing cancer immunotherapy treatments that enable the immune system to attack tumors. The company in 2012 and is based in Cambridge, Massachusetts.


JNCE Latest News Stream


Event/Time News Detail
Loading, please wait...

JNCE Latest Social Stream


Loading social stream, please wait...

View Full JNCE Social Stream

Latest JNCE News From Around the Web

Below are the latest news stories about JOUNCE THERAPEUTICS INC that investors may wish to consider to help them evaluate JNCE as an investment opportunity.

United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.

Yahoo | May 4, 2023

Jounce Therapeutics Announces Closing of Tender Offer

Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value RightsCAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC (“Concentra”), through its wholly owned subsidiary Concentra Merger Sub, Inc. (“Concentra Merger Sub”), has successfully completed

Yahoo | May 4, 2023

The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitable

It is a pleasure to report that the Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) is up 67% in the last quarter. But will...

Yahoo | April 17, 2023

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

Yahoo | April 11, 2023

5 Stocks to Buy as the Drug Industry Rebounds in 2023

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

Yahoo | April 10, 2023

Read More 'JNCE' Stories Here

JNCE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -66.96%
5-year -54.92%
YTD N/A
2023 0.00%
2022 -86.71%
2021 19.29%
2020 -19.82%
2019 159.05%

Continue Researching JNCE

Want to see what other sources are saying about Jounce Therapeutics Inc's financials and stock price? Try the links below:

Jounce Therapeutics Inc (JNCE) Stock Price | Nasdaq
Jounce Therapeutics Inc (JNCE) Stock Quote, History and News - Yahoo Finance
Jounce Therapeutics Inc (JNCE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!